Marshall Wace, LLP Atri Cure, Inc. Transaction History
Marshall Wace, LLP
- $72.2 Billion
- Q2 2024
A detailed history of Marshall Wace, LLP transactions in Atri Cure, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 447,941 shares of ATRC stock, worth $12.6 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
447,941
Previous 961,359
53.41%
Holding current value
$12.6 Million
Previous $29.2 Million
65.12%
% of portfolio
0.01%
Previous 0.05%
Shares
16 transactions
Others Institutions Holding ATRC
# of Institutions
210Shares Held
49.3MCall Options Held
111KPut Options Held
23.8K-
Vanguard Group Inc Valley Forge, PA4.62MShares$130 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.62MShares$130 Million0.0% of portfolio
-
Alliancebernstein L.P. New York, NY4.2MShares$118 Million0.03% of portfolio
-
Champlain Investment Partners, LLC Burlington, VT2.67MShares$75.4 Million0.39% of portfolio
-
Macquarie Group LTD Australia, C32MShares$56.3 Million0.05% of portfolio
About AtriCure, Inc.
- Ticker ATRC
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 46,424,700
- Market Cap $1.31B
- Description
- AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation...